Literature DB >> 1455903

Metabolism of calcium antagonist Ro 40-5967: a case history of the use of diode-array u.v. spectroscopy and thermospray-mass spectrometry in the elucidation of a complex metabolic pathway.

H R Wiltshire1, S R Harris, K J Prior, U M Kozlowski, E Worth.   

Abstract

1. The calcium antagonist, Ro 40-5967, is metabolized to a multitude of products by the rat and drug-related material is excreted predominantly via the bile. 2. Diode-array u.v. spectroscopy, following reverse phase h.p.l.c. separation of the partially purified metabolites, has been used to classify these compounds into six spectral classes which have been correlated with different metabolic reactions. 3. Connection of a mass spectrometer directly to the h.p.l.c. equipment by a thermospray interface, produced useful mass spectra. These, together with the u.v. spectra, enabled the structures of many metabolites to be elucidated. 4. Confirmation of structural assignments was provided by n.m.r. spectra of the major metabolites. 5. Major metabolic pathways included N-demethylation (16% of the biliary metabolites), hydrolysis of the ester side-chain (32%), hydroxylation at 4- (19%) and 5- (29%) positions of the benzimidazole ring, aromatization of the tetrahydronaphthyl system (26%), loss of the benzimidazole (15%) and glucuronidation of hydroxyl groups (81%).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1455903     DOI: 10.3109/00498259209053144

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  2 in total

1.  Effects of mibefradil on intracellular Ca2+ release in cultured rat cardiac fibroblasts and human platelets.

Authors:  M Eberhard; K Miyagawa; K Hermsmeyer; P Erne
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

2.  The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil.

Authors:  Peter H Bui; Arnulfo Quesada; Adrian Handforth; Oliver Hankinson
Journal:  Drug Metab Dispos       Date:  2008-04-14       Impact factor: 3.922

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.